Xiogenix

Meet Todd Farley, our Director of Equipment and Services, and the heart of our service operations. In this short clip, Todd shares why he’s passionate about serving our customers and ensuring their success.   From installations and troubleshooting to preventative maintenance, Todd thrives on solving challenges and improving processes. His dedication to understanding our customers' needs and supporting them on-site helps us build better equipment and deliver exceptional service.   Discover how Xiogenix is committed to supporting your success with innovative solutions and exceptional service: www.xiogenix.com   Rachel Bahr, Allie Schroeder, Sami Reimer, Joshua Jendusa, Luke Iding, Alex Gehl, Jack Leonovicz, Thor Holmgren, Parker Glissendorf, Ethan Hannon, Pete Hirsch, Karlie Bakko, Brittney Reid, Steven Peterson #CustomerServiceExcellence #InnovationInAction #EquipmentAndServices #Xiogenix

👨🔬💬 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐍𝐞𝐰𝐬: 𝟏𝟑𝐭𝐡 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 👩🔬💬 🧬 uniQure has aligned with the FDA on key elements for AMT-130’s Accelerated Approval in Huntington’s disease, using Phase I/II study data and natural history controls as the primary basis for a BLA. The composite Unified Huntington’s Disease Rating Scale will serve as an intermediate clinical endpoint, with cerebrospinal fluid neurofilament light chain reductions supporting therapeutic benefits. 🦠 SpliceBio announced clearance of its IND application for SB-007, a dual AAV gene therapy targeting Stargardt disease, the first Protein Splicing gene therapy in clinical development addressing all ABCA4 mutations. Stargardt disease, caused by large ABCA4 gene mutations, currently lacks approved therapies. SB-007 has shown promising safety and efficacy in preclinical studies and holds Orphan Drug Designation in the US and Europe. 🧬 Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, securing $75 million to advance genetic medicine providing a multi-year runway for clinical advancements and strategic partnerships. Its lead candidate, CRMA-1001, targets chronic hepatitis B and D, showing potential for durable, functional cures. The company plans to expand its pipeline beyond liver-targeted therapies, leveraging its innovative platform and experienced team. 🦠 Brightpath Biotherapeutics and Cellistic have partnered to develop and manufacture iPSC-derived BCMA CAR-NKT cells for a Phase 1 multiple myeloma trial. The collaboration leverages Cellistic’s 3D bioreactor-based Echo platform for scalable, GMP-compliant production, positioning BrightPath as a leader in this field. This approach combines the direct and indirect anti-tumor effects of NKT cells with iPSC technology to overcome manufacturing challenges. 🧬 Tenpoint Therapeutics Ltd and Visus Therapeutics have merged to advance ophthalmic medicines, focusing on BRIMOCHOL™ PF, a once-daily presbyopia eye drop targeting a 2026 US launch. The pipeline includes therapies for cataracts and geographic atrophy, supported by a Crossover financing round. This merger brings together extensive expertise, investors, and a robust product portfolio to address unmet needs in vision care, with BRIMOCHOL™ PF aiming to redefine presbyopia treatment through enhanced efficacy and extended duration. 🦠 Cellipont Bioservices and Xiogenix have partnered to integrate the Ares™ X20 fill-and-finish system into Cellipont's manufacturing processes. This advanced system enhances precision, efficiency, and safety in cell therapy production with automated formulation, precise temperature control, and high throughput. By integrating this advanced technology, Cellipont aims to optimize the manufacturing process further, ensuring the highest standards of quality and safety. 🛎 My aim is to be the messenger when it comes to your CGT news. Follow #mCGT to stay updated! #celltherapy #genetherapy #ATMP

Thanks for the feature @biopharminternational!

We’re excited to officially announce our partnership with Cellipont Bioservices, a leading cell therapy CDMO! Together, we’re bringing the cutting-edge Ares™ X20 fill-and-finish system to the forefront of cell therapy manufacturing, enhancing precision, efficiency, and quality.   This collaboration represents a shared commitment to innovation and excellence in biopharmaceutical technology. We’re thrilled to see how this partnership will advance the field and help deliver life-changing therapies to patients worldwide.   Read the full press release here: https://lnkd.in/euEsFEVz #Xiogenix #CellipontBioservices #ARESX20 #CellAndGeneTherapy #InnovationInBiotech #PartnershipForProgress  

It's the most wonderful time of the year! 🎶❄️ #organizationalclarityblitz As the year comes to a close, take a moment to check in with your team to align and elevate your strategies and execution. ⬆️ What's your dream for 2025? ✨ 🙏 A huge thank you to everyone at Vendura Industries who participated in this session—we're excited to see the incredible outcomes from all the productive discussions. Let's keep building together! 💡💪 #Teamwork #StrategicAlignment #OrganizationalClarity Nathan Jendusa, MBA, MSA, Jerry Jendusa, Rachel Bahr, Sam Hoffman, David Rusher Sr., Megan Wylie

We’re excited to introduce you to Vincent C., one of our trusted collaborators on the Ares X20 project! 🎥 In this interview, Vinny shares his journey, his passion for advancing cell and gene therapy, and his inspiring vision for the future.   💡 From technical expertise to transformative insights, Vinny has played a key role in bringing the Ares X20 to life, a system designed to revolutionize the cell therapy process.   🔗 Watch the interview to learn how Vinny's dedication and hope are driving innovation and impacting lives.

We’re excited to introduce you to Vincent C., one of our trusted collaborators on the Ares X20 project! 🎥 In this interview, Vinny shares his journey, his passion for advancing cell and gene therapy, and his inspiring vision for the future.   💡 From technical expertise to transformative insights, Vinny has played a key role in bringing the Ares X20 to life, a system designed to revolutionize the cell therapy process.   🔗 Watch the interview to learn how Vinny's dedication and hope are driving innovation and impacting lives.

We were thrilled to celebrate the launch of ARES™ X20 with industry leaders like Brian Fry, Senior Director at Cellipont Bioservices. Prior to the event, Brian shared his thoughts on Cell and Gene Therapy, describing it as a field filled with promise.   His sentiment reflects a larger truth: Cell and Gene Therapy represents a new frontier in medicine, offering hope for those battling diseases that have long been considered incurable. This innovation is paving the way for transformative treatments that have the potential to change countless lives.   At Xiogenix, we are committed to driving progress in this critical field and collaborating with others who share our vision for a healthier future! Together, we’re turning promise into reality. Learn more about our work at www.xiogenix.com   #ARESX20 #CellAndGeneTherapy #Innovation #TransformativeHealthcare #HopeThroughHealing

🚛💪 Teamwork Makes the Dream Work! 💪🚛 The day before Thanksgiving, our Xiogenix team came together to pack and ship one of our largest orders yet! Grateful for this amazing team and the difference we’re making together. Wishing everyone a safe and happy Thanksgiving! 🦃✨ Jack Leonovicz, Thor Holmgren, Pete Hirsch, Nicolas Daws, Brittney Reid, Parker Glissendorf, Steven Peterson, Allie Schroeder #Teamwork #ThanksgivingHustle #CustomerFirst #Xiogenix

Still buzzing from the incredible ARES™ X20 launch party! 🎉 The excitement doesn’t end here—this groundbreaking Fill & Finish innovation, and the passion of those involved, continues to inspire us every day. Learn more about what makes the ARES™ X20 such a big deal: https://lnkd.in/gZcYXSr6 Rachel Bahr, Allie Schroeder, Sami Reimer, Steven Peterson, Todd Farley, Luke Iding, Joshua Jendusa, Karlie Bakko, Brittney Reid, Jack Leonovicz, Thor Holmgren, Ethan Hannon, Parker Glissendorf, Megan Wylie, Sam Hoffman, #ARESX20 #CellAndGeneTherapy #LaunchEvent #Xiogenix